In conclusion, we showed that the loss of SMAD1 expression, in AML patient samples and cell lines with KMT2A::AFF1 and KMT2A::MLLT3, might contribute to leukemogenesis by influencing the response to TGF-β and the individual downstream effects of it. This evidence concerns the gene MLLT3 and acute myeloid leukemia.